Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, TOB, Peggy
Search This Board:
Last Post: 4/23/2014 12:52:00 PM - Followers: 190 - Board type: Free - Posts Today: 13




"The Future Of Medicine"

Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 

Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697

Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options



Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.
Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).

The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.

Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug


Dec 10, 2012 Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found to Be Effective Against Multidrug Resistant Uterine Cancer Cells
Dec 5, 2012 Daily Watchlist: Sunshine Biopharma Inc. (OTCBB: SBFM), Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM), Axia Group's (PINKSHEETS: AGIJ), Terralene Fuels Corporation (OTCQB: GSPT)
Dec 4, 2012 Sunshine Biopharma Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Nov 27, 2012 Advanomics Corporation, the Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
Nov 25, 2012 Volume Alerts: Medizone International (OTCQB: MZEI), SportsQuest, Inc. (PINKSHEETS: SPQS), Sunshine Biopharma Inc. (OTCBB: SBFM), Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH)
Nov 13, 2012 Sunshine Biopharma Initiates IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Oct 9, 2012 Sunshine Biopharma Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a
Sept 25, 2012 Les résultats des recherches précliniques sur l'Adva-27a de Sunshine Biopharma, seront publiés dans l'édition d'octobre d'ANTICANCER RESEARCH
Sept 25, 2012 Sunshine Biopharma's Adva-27a Preclinical Research Results to Be Published in October Issue of ANTICANCER RESEARCH
Sept 20, 2012 Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials

11/16/11 Sunshine Biopharma announces successful completion of preclinical studies for Adva-27a, the company's lead anti-cancer compound

10/5/11 Sunshine Biopharma's anti-cancer compound, Adva-27a, found to be a strong Topoisomerase II inhibitor

8/30/11 Clearance of Sunshine Biopharma's anti-cancer compound, Adva-27a, does not involve a toxic intermediate

8/10/11  Sunshine Biopharma Aims to Follow in Herceptin's Footsteps

8/2/11  Sunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success

SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals


SBFM Share Structure


Outstanding 51,391,092 a/o Nov 07, 2012
Float 13,916,529 a/o Mar 15, 2012
Authorized Shares 200,000,000 a/o Dec 31, 2011

31.5 million held by Steve Slilaty, CEO

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Tel: 514-764-9698
Fax: 514-764-9699




#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#10706  Sticky Note SUNSHINE BIOPHARMA INC (quick info) BooDog 09/12/13 07:25:24 AM
#16016   It would be informative, either from them or Citrati 04/23/14 12:52:00 PM
#16015   I prefer to stay away from that sort Doc_John 04/23/14 12:48:27 PM
#16014   Lol Doc_John 04/23/14 11:59:21 AM
#16013   I am curious what is going on at Citrati 04/23/14 11:53:16 AM
#16012   Whatever you do, don't put the words "potatoes" G Bert 04/23/14 11:32:55 AM
#16011   I may call Camille Sebaaly or write to Doc_John 04/23/14 11:29:14 AM
#16010   Definitely the mm's very easy to run us Doc_John 04/23/14 11:26:55 AM
#16009   'Changed my mind. No one's that dumb G Bert 04/23/14 11:21:09 AM
#16008   True dat....some fun conversation until lift-off. Citrati 04/23/14 10:45:46 AM
#16007   Could be someone on the board doing that. G Bert 04/23/14 10:44:25 AM
#16006   LOL, who placed the 911 order...(which mm) ? Citrati 04/23/14 10:18:35 AM
#16005   $SBFM looking like a real winner! .25-30+ in pennyrocks 04/23/14 08:49:14 AM
#16004   CAMILLE SEBAALY CFO WHERE IS THE NEWS???YOU BURNED Angel21stCentury 04/23/14 08:38:44 AM
#16003   And with good clinical trial results, we get G Bert 04/22/14 05:40:32 PM
#16002   Ugh.... sin vester 04/22/14 05:03:00 PM
#16001   Ceo did it again,over and over ,history repeated Cash Monster 04/22/14 04:51:35 PM
#16000   Mr president clinical trials already began in 2011 Cash Monster 04/22/14 04:46:53 PM
#15999   It's the big gale that just sunk this Lavaliotis 04/22/14 04:41:12 PM
#15998   Something is moving this now... YES!!!! sin vester 04/22/14 04:07:23 PM
#15997   I'm buying more.... LOL sin vester 04/22/14 04:06:54 PM
#15996   this lottery ticket needs to hit. LOL sin vester 04/22/14 04:06:36 PM
#15995   Born on date 4/15...came here to warn us...lmao! Smooth 04/22/14 04:04:19 PM
#15994   doesn't matter if that's true or not. This Smooth 04/22/14 04:03:20 PM
#15993   Don't be a bag holder like everyone here. Cash Monster 04/22/14 03:51:58 PM
#15992   There is no cat in the hat. Cash Monster 04/22/14 03:50:38 PM
#15991   Lame, without a doubt. There are only G Bert 04/22/14 03:45:50 PM
#15990   Look how management' swindles updates to it's shareholders Smooth 04/22/14 03:38:37 PM
#15989   But it is a pretty lame PR, aye? Smooth 04/22/14 03:35:44 PM
#15988   This falls under my sleeper category. Other than BooDog 04/22/14 03:14:09 PM
#15987   Congrats, Angel. That almost qualifies as DD. G Bert 04/22/14 03:07:53 PM
#15986   I agree but load up. I sin vester 04/22/14 02:52:03 PM
#15985   Look how management' swindles updates to it's Cash Monster 04/22/14 02:43:13 PM
#15984   What do you want an update on, this Cash Monster 04/22/14 02:28:10 PM
#15983   That's an interesting thought but I wonder if sin vester 04/22/14 01:30:22 PM
#15982   Depends on where they want to market it. G Bert 04/22/14 12:54:49 PM
#15981   We'll know after Slilaty does imo. fwiw. A BooDog 04/22/14 12:47:52 PM
#15980   Well hopefully news will come out to update sin vester 04/22/14 12:27:56 PM
#15979   They are testing it by writing on a Cash Monster 04/22/14 12:16:23 PM
#15978   You know Investors Relations Camille swindle Sebaaly. Call Cash Monster 04/22/14 12:10:49 PM
#15977   But if this is being tested in Canada, sin vester 04/22/14 12:08:19 PM
#15976   How? Doc_John 04/22/14 11:45:32 AM
#15975   Well said mr president, don't forget to add Cash Monster 04/22/14 11:25:36 AM
#15973   Like most pharmas, taking way too long for G Bert 04/22/14 10:56:29 AM
#15970   All great, and all lies. Cash Monster 04/22/14 10:44:50 AM
#15968   There is plenty more news to come, all Doc_John 04/22/14 10:31:31 AM
#15967   What interviews??? Ahhhhhh your talking about those dark, Cash Monster 04/22/14 10:30:09 AM
#15966   I just hope that once he does get Doc_John 04/22/14 10:27:05 AM
#15965   Hey G Bert ... what's the latest with Peggy 04/22/14 10:22:56 AM
#15964   Read this; Doc_John 04/22/14 10:19:55 AM
#15962   There is no dilution going on!!! This management Doc_John 04/22/14 10:17:02 AM